- Johnson & Johnson beat Q1 consensus on earnings, revenue.
- JNJ pops 2% on news, moving above $166 resistance point.
- Sales revenue rises 5.6% YoY.
- Johnson & Johnson raises full-year guidance.
Johnson & Johnson (JNJ) stock rose 2% in Tuesday's premarket after the healthcare and consumer goods conglomerate reported first quarter adjusted earnings per share (EPS) of $2.68, 18 cents above Wall Street analysts' projections. Revenue of $24.7 billion was also $1.1 billion above consensus. JNJ stock broke above its $166 resistance barrier.
Johnson & Johnson stock news: 2023 guidance raised
Despite poor US retail spending data from last week, Johnson & Johnson's suite of pharamceuticals, medical devices and consumer staples were in strong demand with revenue rising 5.6% YoY. Most of this growth was domestic with the US seeing a 9.7% sales gain YoY. Its foreign operations saw just 1.8% growth YoY.
In addition, management does not seem to see storm clouds on the horizon like a lot of other firms. Full-year 2023 revenue guidance was raised to a range of $97.9 billion to $98.9 billion. The range was boosted by exactly $1 billion on the top and bottom from prior guidance. The range is above Wall Street consensus of $97.65 billion.
Johnson & Johnson also raised its prior range for adjusted earnings of $10.45 to $10.65 per share to $10.60 to $10.70 per share. This is well above Wall Street's projection for $10.51.
“Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Chairman and CEO Joaquin Duato. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”
The company did not report any new information regarding its decision two weeks ago to refile bankruptcy proceedings for its TMT subsidiary that houses its talc-based baby powder business, which came under scrutiny for claims that it causes cancer. The company announced on April 4 that it is willing to resolve all claims for $8.9 billion paid over 25 years.
Johnson & Johnson stock forecast
The weekly chart below shows JNJ stock struggling at the $166 resistance point over the past few weeks. That level is right below the 30-week moving average. However, JNJ stock has shot up to near $169 in the premarket, even breaking above the 30-week moving average in a testament to its bearish year to date price action coming to an end. Expect bulls to target $180 next. That price level is where JNJ stock ran into resistance back in December. The Moving Average Convergence Divergence (MACD) indicator has also crossed over on the weekly chart, which is much more bullish of a signal than a mere daily chart crossover.
JNJ weekly chart
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD drops below 1.0550 ahead of German inflation data
EUR/USD extends losses below 1.0550 in the European session on Thursday. The pair's downside could be attributed to French political worries and a broad US Dollar rebound amid the cautious mood. Traders remain wary due to mounting trade war risks. Germany's inflation data is in focus.
GBP/USD holds lower ground near 1.2650
GBP/USD remains pressured near 1.2600 in European trading on Thursday as the US Dollar picks up haven dmeand on deteriorating risk sentiment. A sense of cautiom prevails amid Trump's tariff plans even though liquidity remains thin on Thanksgiving Day.
Gold price bulls remain on the sidelines on stronger USD, positive risk tone
Gold price (XAU/USD) reverses an intraday dip to the $2,620 area and trades near the daily high during the first half of the European session on Thursday, albeit it lacks bullish conviction. Investors remain concerned that US President-elect Donald Trump's tariff plans will impact the global economic outlook.
Fantom bulls eye yearly high as BTC rebounds
Fantom (FTM) continued its rally and rallied 8% until Thursday, trading above $1.09 after 43% gains in the previous week. Like FTM, most altcoins have continued the rally as Bitcoin (BTC) recovers from its recent pullback this week.
Eurozone PMI sounds the alarm about growth once more
The composite PMI dropped from 50 to 48.1, once more stressing growth concerns for the eurozone. Hard data has actually come in better than expected recently – so ahead of the December meeting, the ECB has to figure out whether this is the PMI crying wolf or whether it should take this signal seriously. We think it’s the latter.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.